Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Unum Therapeutics Inc (UMRX)

Unum Therapeutics Inc (UMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 99,802
  • Shares Outstanding, K 42,469
  • Annual Sales, $ 22,500 K
  • Annual Income, $ -31,830 K
  • 60-Month Beta 3.97
  • Price/Sales 4.42
  • Price/Cash Flow N/A
  • Price/Book 3.81
Trade UMRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.76
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 11/10/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.04
  • Number of Estimates 1
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.39
  • Growth Rate Est. (year over year) +89.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.17 +8.29%
on 09/08/20
3.05 -22.95%
on 09/18/20
+0.15 (+6.82%)
since 09/04/20
3-Month
0.60 +291.01%
on 07/06/20
3.72 -36.83%
on 07/10/20
+1.91 (+428.33%)
since 07/02/20
52-Week
0.29 +696.61%
on 04/09/20
3.72 -36.83%
on 07/10/20
+0.88 (+59.86%)
since 10/04/19

Most Recent Stories

More News
SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics

PRAGUE, Czech Republic and CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced that it has acquired the rights...

UMRX : 2.35 (+0.43%)
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Unum Therapeutics Inc. for Potential Breach of Fiduciary Duty Claims

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Unum Therapeutics Inc. (NASDAQ:...

UMRX : 2.35 (+0.43%)
Unum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates

CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial...

UMRX : 2.35 (+0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 2.45
1st Resistance Point 2.40
Last Price 2.35
1st Support Level 2.31
2nd Support Level 2.27
3rd Support Level N/A

See More

52-Week High 3.72
Fibonacci 61.8% 2.41
Last Price 2.35
Fibonacci 50% 2.01
Fibonacci 38.2% 1.60
52-Week Low 0.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar